Additional research is required, but we cannot therefore rule out the possibility that precision therapy strategies based on NDP52 could become crucial in the development of drugs for AD, MS, CD, and possibly other inflammatory diseases linked to Tau accumulation such as postencephalitic parkinsonism [127], or the chronic traumatic encephalopathy [128]. Here, CALCOCO2 is linked to myeloid sarcoma.